1. Scrip
  2. >>New Products

AbbVie’s Humira Succession Plan Begins Taking Shape With Skyrizi US Approval

 
• By Joseph Haas

Central to AbbVie’s plans to endure biosimilar erosion to Humira, Skyrizi gets US approval in psoriasis, with approval of upadacitinib expected in RA this year.

Rubber stamping that says 'FDA Approved'.

AbbVie Inc. long has pointed to interleukin-23 inhibitor Skyrizi (risankizumab-rzaa) as a key plank of its growth strategy for biosimilar competition to top-seller Humira (adalimumab); following previous approvals in Japan and Canada, the biologic now has obtained US approval for moderate-to-severe plaque psoriasis in adult patients suitable for systemic therapy or phototherapy.

The pharma announced the on-time US FDA approval after markets closed on 23 April, with plans to launch the drug in early May. AbbVie told Scrip that $59,000 is the product’s wholesale acquisition price (WAC) in the maintenance setting, lower than pricing for “the most widely prescribed biologic treatments” for psoriasis

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.